Cargando…
肺鳞癌的免疫治疗进展
In recent years, squamous non-small cell lung cancer (NSCLC) didn't progress much in chemotherapy or target therapy. However, immunotherapy has made breakthroughs in treating squamous NSCLC. Immunotherapy includes two main broad classes of immune checkpoint inhibitors and therapeutic vaccines....
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973414/ https://www.ncbi.nlm.nih.gov/pubmed/27760599 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.09 |
| _version_ | 1783326626075901952 |
|---|---|
| collection | PubMed |
| description | In recent years, squamous non-small cell lung cancer (NSCLC) didn't progress much in chemotherapy or target therapy. However, immunotherapy has made breakthroughs in treating squamous NSCLC. Immunotherapy includes two main broad classes of immune checkpoint inhibitors and therapeutic vaccines. Immune checkpoint inhibitors, including anti cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and anti programmed death receptor 1 (PD-1) antibodies, have been tested in the phase Ⅱ/Ⅲ clinical trials and have demonstrated promising outcomes. Immunotherapy will become an important treatment for squamous NSCLC. |
| format | Online Article Text |
| id | pubmed-5973414 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-59734142018-07-06 肺鳞癌的免疫治疗进展 Zhongguo Fei Ai Za Zhi 肺鳞癌专题 In recent years, squamous non-small cell lung cancer (NSCLC) didn't progress much in chemotherapy or target therapy. However, immunotherapy has made breakthroughs in treating squamous NSCLC. Immunotherapy includes two main broad classes of immune checkpoint inhibitors and therapeutic vaccines. Immune checkpoint inhibitors, including anti cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and anti programmed death receptor 1 (PD-1) antibodies, have been tested in the phase Ⅱ/Ⅲ clinical trials and have demonstrated promising outcomes. Immunotherapy will become an important treatment for squamous NSCLC. 中国肺癌杂志编辑部 2016-10-20 /pmc/articles/PMC5973414/ /pubmed/27760599 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.09 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
| spellingShingle | 肺鳞癌专题 肺鳞癌的免疫治疗进展 |
| title | 肺鳞癌的免疫治疗进展 |
| title_full | 肺鳞癌的免疫治疗进展 |
| title_fullStr | 肺鳞癌的免疫治疗进展 |
| title_full_unstemmed | 肺鳞癌的免疫治疗进展 |
| title_short | 肺鳞癌的免疫治疗进展 |
| title_sort | 肺鳞癌的免疫治疗进展 |
| topic | 肺鳞癌专题 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973414/ https://www.ncbi.nlm.nih.gov/pubmed/27760599 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.09 |
| work_keys_str_mv | AT fèilínáidemiǎnyìzhìliáojìnzhǎn AT fèilínáidemiǎnyìzhìliáojìnzhǎn |